Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists watch brain and heart in stroke survivors

NCT ID NCT07322107

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at brain activity and heart patterns in people who have had a stroke and compares them to healthy adults. Researchers use special head sensors and heart monitors to measure differences. The goal is to better understand how stroke changes the brain and heart. No treatments or drugs are tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 45 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 19 to 80 years, including patients with intracerebral hemorrhage, patients with cerebral infarction, and neurologically healthy adult volunteers who meet the study's inclusion and exclusion criteria

Ages

19 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Intracerebral Hemorrhage Group (Stroke Patients) Adults aged 19 to 80 years. Diagnosed with intracerebral hemorrhage based on clinical evaluation and neuroimaging findings. Able to read and understand the participant information sheet and consent form, and capable of completing questionnaires in the study language. Voluntarily agrees to participate in the study, provides written informed consent, and is able to participate for the entire study period. Cerebral Infarction Group (Stroke Patients) Adults aged 19 to 80 years. Diagnosed with cerebral infarction (ischemic stroke) based on clinical evaluation and neuroimaging findings. Able to read and understand the participant information sheet and consent form, and capable of completing questionnaires in the study language. Voluntarily agrees to participate in the study, provides written informed consent, and is able to participate for the entire study period. Healthy Adult Group Adults aged 19 to 80 years. No history of stroke or transient ischemic attack (TIA). No major stroke risk factors such as hypertension, diabetes mellitus, or hyperlipidemia. No chronic diseases, including cardiovascular disease, chronic kidney disease, or chronic pulmonary disease. No psychiatric disorders, such as depression or schizophrenia. Not taking medications that may affect cerebral hemodynamics, including antihypertensive agents, anticoagulants, antiplatelet agents, or antidepressants. Able to read and understand the participant information sheet and consent form, and capable of completing questionnaires in the study language. Voluntarily agrees to participate in the study, provides written informed consent, and is able to participate for the entire study period. Exclusion Criteria: * Participants meeting any of the following exclusion criteria will not be enrolled in the study. History of head trauma or cranial surgery within the past 6 months with wounds that have not yet fully healed. Current diagnosis of a severe psychiatric disorder, such as schizophrenia, major depressive disorder, or bipolar disorder. Participation in another clinical study and intake of an investigational drug within the past 30 days. Women who are pregnant or breastfeeding. Presence of an acute infection or inflammatory disease. Inability to adequately understand the study procedures or lack of voluntary consent to participate. Any other clinically significant finding that, in the judgment of the principal investigator or designated study physician, makes the individual unsuitable for participation in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebral infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rehab lab, Pusan National University Yangsan Hospital

    Yangsan, Gyeongsangnam-do, 50612, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.